What is already known about this subject?
- Despite improved HCT outcome in patients with high-risk TM using
F-araA based regimen, rejection and toxicities still remain a major
concern.
- Limited inconclusive data on F-araA PK in non-uniform diagnoses and
dose-exposure response relationship was not evaluated in patients with
high-risk TM.
- Sparse data on F-araA pharmacogenomics.